Cancer immunotherapies can yield poor results, and one of the reasons is that activation of AhR by kynurenine leads to the formation of immunotolerant dendritic and regulatory T cells, which contribute to the creation of an immunosuppressive tumor microenvironment [67]. The gene discussed is AHR; the disease is neoplasm.